News | Radiation Therapy | April 07, 2022

ASTRO released a statement in response to the proposed rule issued April 6 by CMS that will delay the Radiation Oncology (RO) Model, which was scheduled to go into effect in January 1, 2023

The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, MD, FASTRO, in response to the Centers for Medicare and Medicaid Services' (CMS) decision to delay the start of the Radiation Oncology Alternative Payment Model (RO-APM)

Getty Images


April 7, 2022 — The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, MD, FASTRO, in response to the Centers for Medicare and Medicaid Services' (CMS) decision to delay the start of the Radiation Oncology Alternative Payment Model (RO-APM):

"The Centers for Medicare and Medicaid Services today delayed the Radiation Oncology Alternative Payment Model start date from January 1, 2023, to a date to be determined through future rulemaking.  ASTRO remains hopeful that during this process, CMS also makes the adjustments recommended by Congress and the broad coalition of stakeholders within the radiation oncology community as we remain concerned that the model in its current form is too punitive for clinics. We remain committed to value-based care in radiation oncology. We believe that the modifications proposed by ASTRO and the radiation oncology community will ensure successful participation among physicians and facilities and produce significant savings for the Medicare program.  We continue to believe that episodic payments for radiation therapy services have great potential to improve quality and equity while reducing cancer care costs, and we will continue to advocate for proposals that achieve these goals.”

For more information: www.astro.org

Related CMS Content:

ASTRO Urges Congress to Pass Legislation Delaying RO Model and Protecting Medicare Beneficiaries' Access to Care

ASTRO Deeply Concerned and Disappointed Over CMS 2022 Final Rules

Senators and representatives unite to call on CMS to protect patient access to high-quality radiation treatments

 


Related Content

News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
Subscribe Now